Skip to main content
. 2022 Sep 20;9:977761. doi: 10.3389/fvets.2022.977761

Table 5.

Detection of FMDV from bovine tissue samples collected from Nigeria using the SAT1, SAT3 and SAT2 topotype VII rRT-PCR assays.

Isolate Serotype/Topotype/Lineage SAT1 Cq SAT2 Cq SAT3 Cq FMDV 3D Cq Xeno Cq
O/NIG/BAU/BAU/1/2020 O/EA3 No Cq No Cq No Cq 17.96 31.36
O/NIG/BAU/BAU/5/2020 O/EA3 No Cq No Cq No Cq 23.12 31.59
O/NIG/BAU/BAU/13/2020 O/EA3 No Cq No Cq No Cq 24.04 31.11
O/NIG/BAU/BAU/14/2020 O/EA3 No Cq No Cq No Cq 21.33 31.44
O/NIG/BAU/BAU/17/2020 O/EA3 No Cq No Cq No Cq 25.77 31.83
O/NIG/BAU/BAU/21/2020 O/EA3 No Cq No Cq 37.81 16.22 31.53
O/NIG/BAU/BAU/22/2020 O/EA3 No Cq No Cq No Cq 15.73 32.14
SAT2/NIG/PL/BLD/1/2020 SAT2/VII No Cq 19.57 No Cq 13.73 31.82
SAT2/NIG/PL/BLD/2/2020 SAT2/VII No Cq 21.01 No Cq 15.32 31.63
SAT2/NIG/PL/BLD/3/2020 SAT2/VII No Cq 14.84 No Cq 9.82 31.41
SAT2/NIG/PL/BLD/5/2020 SAT2/VII No Cq 16.63 No Cq 11.80 31.04
SAT2/NIG/PL/BLD/6/2020 SAT2/VII No Cq 22.26 No Cq 15.79 31.20
SAT2/NIG/PL/BLD/7/2020 SAT2/VII No Cq 21.25 No Cq 15.22 30.99
SAT2/NIG/PL/BLD/8/2020 SAT2/VII No Cq 14.69 No Cq 10.34 31.37
O/NIG/PL/BLD/9/2020 O/EA3 No Cq No Cq No Cq 26.64 31.72
O/NIG/KN/BMF/1/2020 O/EA3 No Cq No Cq No Cq 19.92 31.46
O/NIG/KN/BMF/2/2020 O/EA3 No Cq No Cq No Cq 15.76 32.18
O/NIG/KN/BMF/3/2020 O/EA3 No Cq No Cq No Cq 17.78 31.60
O/NIG/KN/BMF/4/2020 O/EA3 No Cq No Cq 36.13 18.17 31.50
O/NIG/KN/BMF/5/2020 O/EA3 No Cq No Cq No Cq 27.26 31.94
O/NIG/KN/RMG/1/2020 O/EA3 No Cq No Cq No Cq 18.34 31.46
O/NIG/PL/BK/1/2020 O/EA3 No Cq No Cq No Cq 16.77 31.29
SAT2/NIG/PL/BK/2/ SAT2/VII No Cq 28.90 No Cq 22.17 30.84
O/NIG/PL/BK/3/2020 O/EA3 No Cq No Cq No Cq 18.08 31.00
O/NIG/PL/BK/4/2020 O/EA3 No Cq No Cq No Cq 20.78 31.37
A/NIG/PL/BK/5/2020 A/WAG/IV No Cq No Cq No Cq 13.85 32.71
O/NIG/PL/BK/6/2020 O/EA3 No Cq No Cq No Cq 23.23 31.77
A/NIG/PL/BK/7/2020 A/WAG/IV No Cq No Cq No Cq 17.21 32.21
SAT2/NIG/PL/BK/8/2020 SAT2/VII No Cq 28.62 No Cq 21.72 30.60
O/NIG/PL/BK/31/2020 O/EA3 No Cq No Cq No Cq 25.14 32.42
O/NIG/PL/BK/32/2020 O/EA3 No Cq No Cq No Cq 25.43 32.05
O/NIG/PL/BK/33/2020 O/EA3 No Cq No Cq No Cq 23.00 32.31
O/NIG/KD/ZA/1/2020 O/EA3 No Cq No Cq No Cq 19.77 30.67
O/NIG/KD/ZA/2/2020 O/EA3 No Cq 43.16 No Cq 15.72 30.70
O/NIG/KD/ZA/4/2020 O/EA3 No Cq No Cq No Cq 24.98 30.63
O/NIG/KD/ZA/5/2020 O/EA3 No Cq No Cq No Cq 14.16 31.73
O/NIG/KN/KN/1/2020 O/EA3 No Cq No Cq No Cq 18.37 30.94
O/NIG/KN/KN/2/2020 O/EA3 No Cq No Cq No Cq 17.47 30.81
SAT2/NIG/PL/JS/1/2020 SAT2/VII No Cq 19.75 No Cq 14.17 31.26
SAT2/NIG/PL/JS/2/2020 SAT2/VII No Cq 18.87 35.56 13.69 31.32
O/NIG/KT/KT/1/2020 O/EA3 No Cq No Cq No Cq 17.02 30.70
O/NIG/KT/KT/2/2020 O/EA3 No Cq No Cq No Cq 20.58 31.38
O/NIG/KT/KT/3/2020 O/EA3 No Cq No Cq No Cq 13.78 32.19
O/NIG/BAU/TR/1/2020 O/EA3 No Cq No Cq No Cq 19.10 31.70
O/NIG/PL/RY/1/2020 O/EA3 No Cq 27.13 No Cq 24.91 31.63
SAT2/NIG/PL/RY/2/2020 SAT2/VII No Cq 17.09 No Cq 15.79 31.49
SAT2/NIG/PL/RY/3/2020 SAT2/VII No Cq 28.58 No Cq 21.78 31.00
O/NIG/KD/KD/1/2020 O/EA3 No Cq No Cq No Cq 21.86 31.22
O/NIG/KD/KD/2/2020 O/EA3 No Cq No Cq No Cq 21.04 30.89
O/NIG/KD/KD/3/2020 O/EA3 No Cq No Cq No Cq 15.74 31.35
O/NIG/KD/KD/4/2020 O/EA3 No Cq No Cq No Cq 16.86 31.56
O/NIG/KD/KD/5/2020 O/EA3 No Cq No Cq No Cq 14.70 31.42
A/NIG/KD/KGR/1/2020 A/WAG/IV No Cq No Cq No Cq 23.04 31.92
A/NIG/KD/KGR/2/2020 A/WAG/IV No Cq No Cq No Cq 22.21 31.98
A/NIG/KD/KGR/3/2020 A/WAG/IV No Cq No Cq No Cq 11.91 32.07
A/NIG/KD/KGR/4/2020 A/WAG/IV No Cq No Cq No Cq 26.40 31.90
A/NIG/KD/KGR/7/2020 A/WAG/IV No Cq No Cq No Cq 17.28 32.06
A/NIG/KD/KGR/8/2020 A/WAG/IV No Cq No Cq No Cq 16.31 31.71
A/NIG/KD/KGR/9/2020 A/WAG/IV No Cq No Cq No Cq 23.03 31.59
A/NIG/KD/KGR/10/2020 A/WAG/IV No Cq No Cq No Cq 18.33 31.26
A/NIG/KD/KGR/11/2020 A/WAG/IV No Cq No Cq No Cq 21.92 32.27
A/NIG/KD/KGR/14/2020 A/WAG/IV No Cq No Cq No Cq 21.68 32.11
O/NIG/PL/KAN/1/2020 O/EA3 No Cq No Cq No Cq 18.67 32.88
O/NIG/PL/KAN/2/2020 O/EA3 No Cq No Cq No Cq 14.07 32.48
O/NIG/PL/KAN/3/2020 O/EA3 No Cq No Cq No Cq 15.12 32.35
O/NIG/PL/KAN/4/2020 O/EA3 No Cq No Cq No Cq 12.61 32.37
O/NIG/PL/KAN/5/2020 O/EA3 No Cq No Cq No Cq 14.17 32.28
O/NIG/PL/KAN/6/2020 O/EA3 No Cq No Cq No Cq 15.89 31.84
O/NIG/AD/GMB/2/2020 O/EA3 No Cq No Cq No Cq 19.98 32.24
O/NIG/AD/GMB/3/2020 O/EA3 No Cq No Cq No Cq 24.28 31.49
O/NIG/AD/GMB/4/2020 O/EA3 No Cq No Cq No Cq 23.79 31.99
O/NIG/AD/GMB/5/2020 O/EA3 No Cq No Cq No Cq 22.12 31.97
O/NIG/PL/KA/1/2020 O/EA3 No Cq No Cq No Cq 16.53 32.39
O/NIG/PL/KA/2/2020 O/EA3 No Cq No Cq No Cq 16.60 32.58
SAT2/NIG/PL/BL/1/2020 SAT2/VII No Cq 22.44 No Cq 16.46 33.89
SAT2/NIG/PL/BL/2/2020 SAT2/VII No Cq 13.11 No Cq 10.17 32.56
SAT2/NIG/PL/BL//3/2020 SAT2/VII No Cq 15.71 No Cq 11.45 32.82
SAT2/NIG/PL/BL/4/2020 SAT2/VII No Cq 19.22 No Cq 14.75 33.54
SAT2/NIG/PL/BL/6/2020 SAT2/VII No Cq 14.02 No Cq 12.19 32.70
SAT2/NIG/PL/BL/7/2020 SAT2/VII No Cq 16. No Cq 12.03 32.90
SAT2/NIG/PL/BL/8/202 SAT2/VII No Cq 19.95 No Cq 15.62 32.45
SAT2/NIG/PL/BL/9/2020 SAT2/VII No Cq 22.35 No Cq 16.75 32.29
SAT2/NIG/PL/BL/10/2020 SAT2/VII No Cq 15.67 No Cq 11.64 32.97
SAT2/NIG/PL/BL/11/2020 SAT2/VII No Cq 12.81 No Cq 9.92 32.97
SAT2/NIG/PL/BL/12/2020 SAT2/VII No Cq 24.16 No Cq 19.50 32.76
O/NIG/PL/JE/13/2020 O/EA3 No Cq 34.90 No Cq 28.71 33.25
O/NIG/PL/JE/16/2020 O/EA3 No Cq 35.56 No Cq 29.15 32.76
O/NIG/PL/JE/17/2020 O/EA3 No Cq No Cq No Cq 15.51 33.26
O/NIG/PL/JE/19/2020 O/EA3 No Cq 38.54 No Cq 15.42 32.29
O/NIG/PL/JN/20/2020 O/EA3 No Cq 40.46 No Cq 20.96 32.11
O/NIG/PL/JN/21/2020 O/EA3 No Cq 30.87 No Cq 18.87 32.11
O/NIG/PL/JN/22/2020 O/EA3 No Cq No Cq No Cq 24.12 31.80
O/NIG/PL/JN/23/2020 O/EA3 No Cq No Cq No Cq 22.48 32.55
O/NIG/PL/JN/24/2020 O/EA3 No Cq 30.11 No Cq 16.45 32.31
O/NIG/PL/JN/25/2020 O/EA3 No Cq No Cq No Cq 23.03 32.10
O/NIG/PL/JN/26/2020 O/EA3 No Cq No Cq No Cq 23.87 31.97
O/NIG/PL/JN/27/2020 O/EA3 No Cq No Cq No Cq 19.80 32.13
O/NIG/PL/JN/28/2020 O/EA3 No Cq 33.30 No Cq 18.69 32.08
O/NIG/PL/JN/29/2020 O/EA3 No Cq No Cq No Cq 23.24 31.19

Next-generation sequencing was utilized to identify FMDV serotype. Samples are considered positive when the quantification cycle (Cq) is ≤ 35.99 for SAT1, SAT2, topotype VII, SAT3, FMDV pan-serotype 3D and Xeno control assays.

The colours used to indicate each of the Foot-and-Mouth Disease virus serotypes. Serotype O is blue, serotype A is red, serotype Asia1 is grey, serotype SAT1 is yellow, serotype SAT2 is purple and serotype SAT3 is orange. When the Cq value cells are highlighted with either yellow, purple or orange, it means that a Cq value was produced for this particular viral isolate or sample. If the yellow, purple or orange is darker and the Cq value is <35.99 then the sample was positive when evaluated by the corresponding assay. If the filled cell is the lighter version of the colour, it indicates that although a Cq value was produced, it is >35.99 and the sample is considered negative.